This update to the AAN’s 2002 published
guideline on disease modifying therapies (DMTs) for MS reviews the evidence
and provides recommendation statements regarding starting, switching, and
stopping DMTs for MS.
The AAN seeks comments on the following
issues:
›
Interpretation and inclusion of evidence
›
Clarity and comprehensiveness of
conclusion statements
The AAN is committed to developing
guidelines and evidence-based documents that incorporate patient and
caregiver perspectives in a meaningful way.
In addition to the draft
manuscript of the full guideline provided for review, there is an
accompanying summary version for lay stakeholders, such as patients,
caregivers, and advocates, who wish to provide feedback.
This guideline manuscript draft and
accompanying public summary are made available at this time only for the
purpose of obtaining comments from professionals and public stakeholders. Because these documents are not in
their final, publishable form, we ask that you maintain discretion by
refraining from publishing, posting, disseminating, or otherwise releasing
the contents of these documents until further notice is received from the
AAN.
Click the link showing above, to comment
MS Views and News Providing educational information, resources and services for those affected by MS
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
